SG/CALL/MODERNA/165/0.1/20.12.24 | Market Closed - Euronext Paris 12:30:01 2024-07-12 pm EDT | ||
| 0.885 EUR | +5.99% |
|
| Current month | +43.20% | ||
| 1 month | -48.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.895 | +7.19% |
| 24-07-11 | 0.835 | +21.90% |
| 24-07-10 | 0.685 | 0.00% |
| 24-07-09 | 0.685 | +1.48% |
| 24-07-08 | 0.675 | +8.00% |
Real-time Euronext Paris
Last update July 12, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 499WS | |
| ISIN | DE000SY0EYC7 |
| Date issued | 2024-05-16 |
| Strike | 165 $ |
| Maturity | 2024-12-20 (160 Days) |
| Parity | 10 : 1 |
| Emission price | 1.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.095 € |
|---|---|
| Lowest since issue | 0.585 € |
| Spread | 0.01 € |
| Spread % | 1.12% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.5
USD
Average target price
145.9
USD
Spread / Average Target
+20.12%
- Stock Market
- Warrants
- 499WS Warrant
